Tags

Type your tag names separated by a space and hit enter

Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis.
J Dermatolog Treat. 2004 Jun; 15(3):169-78.JD

Abstract

OBJECTIVE

This randomized, double-blind, multi-centre study compared the long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids (TCS) in 658 adults with moderate-severe atopic dermatitis (AD).

METHODS

Patients applied either pimecrolimus or TCS (i.e. 0.1% triamcinolone acetonide cream and/or 1% hydrocortisone acetate cream) twice daily to all affected areas until complete clearance or for up to 1 year. The study was approved by the institutional review board or ethics committee at each centre.

RESULTS

A majority of patients treated with either pimecrolimus or TCS used the drug on a continuous basis over 1 year. In patients who had >30% of the body surface involved by AD, the incidence rate of all skin infections was significantly lower in the pimecrolimus group than in the TCS group (95% CI of the treatment difference: -25.3% to -3.4%). The most frequent application site reaction was burning (25.9% of patients on pimecrolimus and 10.9% on TCS), which was transient and mild-moderate in most cases. Three TCS-treated patients reported skin striae. There were no treatment-related serious or clinically significant systemic adverse events. Efficacy was better in patients on continuous TCS therapy, although patients completing the study were similarly well-controlled in both groups. About 42% of the pimecrolimus-treated patients were maintained for 1 year without TCS.

CONCLUSION

Pimecrolimus demonstrated a favourable safety profile when used to treat adult patients with moderate-severe AD for up to 1 year. A significant proportion of patients could be maintained without TCS for a year.

Authors+Show Affiliations

Universitätsklinikum Münster, Hautklinik, Muenster Germany. luger@uni-muenster.deNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15204150

Citation

Luger, T A., et al. "Long-term Safety and Tolerability of Pimecrolimus Cream 1% and Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis." The Journal of Dermatological Treatment, vol. 15, no. 3, 2004, pp. 169-78.
Luger TA, Lahfa M, Fölster-Holst R, et al. Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis. J Dermatolog Treat. 2004;15(3):169-78.
Luger, T. A., Lahfa, M., Fölster-Holst, R., Gulliver, W. P., Allen, R., Molloy, S., Barbier, N., Paul, C., & Bos, J. D. (2004). Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis. The Journal of Dermatological Treatment, 15(3), 169-78.
Luger TA, et al. Long-term Safety and Tolerability of Pimecrolimus Cream 1% and Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis. J Dermatolog Treat. 2004;15(3):169-78. PubMed PMID: 15204150.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis. AU - Luger,T A, AU - Lahfa,M, AU - Fölster-Holst,R, AU - Gulliver,W P, AU - Allen,R, AU - Molloy,S, AU - Barbier,N, AU - Paul,C, AU - Bos,J D, PY - 2004/6/19/pubmed PY - 2004/8/6/medline PY - 2004/6/19/entrez SP - 169 EP - 78 JF - The Journal of dermatological treatment JO - J Dermatolog Treat VL - 15 IS - 3 N2 - OBJECTIVE: This randomized, double-blind, multi-centre study compared the long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids (TCS) in 658 adults with moderate-severe atopic dermatitis (AD). METHODS: Patients applied either pimecrolimus or TCS (i.e. 0.1% triamcinolone acetonide cream and/or 1% hydrocortisone acetate cream) twice daily to all affected areas until complete clearance or for up to 1 year. The study was approved by the institutional review board or ethics committee at each centre. RESULTS: A majority of patients treated with either pimecrolimus or TCS used the drug on a continuous basis over 1 year. In patients who had >30% of the body surface involved by AD, the incidence rate of all skin infections was significantly lower in the pimecrolimus group than in the TCS group (95% CI of the treatment difference: -25.3% to -3.4%). The most frequent application site reaction was burning (25.9% of patients on pimecrolimus and 10.9% on TCS), which was transient and mild-moderate in most cases. Three TCS-treated patients reported skin striae. There were no treatment-related serious or clinically significant systemic adverse events. Efficacy was better in patients on continuous TCS therapy, although patients completing the study were similarly well-controlled in both groups. About 42% of the pimecrolimus-treated patients were maintained for 1 year without TCS. CONCLUSION: Pimecrolimus demonstrated a favourable safety profile when used to treat adult patients with moderate-severe AD for up to 1 year. A significant proportion of patients could be maintained without TCS for a year. SN - 0954-6634 UR - https://www.unboundmedicine.com/medline/citation/15204150/Long_term_safety_and_tolerability_of_pimecrolimus_cream_1_and_topical_corticosteroids_in_adults_with_moderate_to_severe_atopic_dermatitis_ L2 - https://www.tandfonline.com/doi/full/10.1080/09546630410033781 DB - PRIME DP - Unbound Medicine ER -